The non-invasive cancer diagnostics market is projected to grow at an annualized rate of ~20%: By Ro

Roots Analysis has done a detailed study on Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 350+ page report, which features 150+ figures and 200+ tables, please visit this –

Key Market Insights
 Presently, nearly 300 non-invasive diagnostic tests, designed for the detection of various types of cancers, are either already available in the market or under development across the world
 Several modern diagnostic tests claim to be capable of offering results in relatively short time periods, thereby, facilitating early diagnosis that is particularly beneficial in the treatment of different types of cancers
 Over time, big pharma players have initiated product development programs, having invested significant capital, time and effort, on non-invasive diagnostic solutions for use across different oncological indications
 Investors, having realized the untapped opportunity within this emerging segment of the cancer diagnostics market, have invested over USD 3 billion across 120 instances in the period between 2015 and 2019
 The growing interest in this field is also reflected in the partnership activity; deals inked in the recent past are focused on a diverse range of tumor markers, involving both international and indigenous stakeholders

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Leave a Reply

Your email address will not be published. Required fields are marked *